Follicum reports revised data from a Phase IIa study of the tissue repairing peptide FOL-005 for the treatment of hair loss (alopecia).
The revised data are based on an independent review that was conducted due to errors detected in the performance analysis presented by the company on May 6, 2021. The revised results show no significant differences compared to what was previously reported and the company stands by the decision to discontinue development of the product for the treatment of hair loss, it states in a press release. However, Follicum will continue to explore opportunities to further develop FOL-005 in other disease areas.
“The company stands by the decision to discontinue development of the product for the treatment of hair loss.”
“Having scrutinized the previously communicated study results, our conclusion remains that the company should not allocate additional resources to the development of FOL-005 for the treatment of hair loss. Instead, we will focus on our diabetes drug project, while evaluating other opportunities to utilize our tissue repairing peptides and our unique formulation technology in other disease areas,” says Follicum’s CEO, Kim Arvid Nielsen.
Photo of Kim Arvid Nielsen: Follicum